Molbio Diagnostics Share Price: Stock Lists at 21% Premium on NSE and BSE

Mumbai | August 17, 2026.

Molbio Diagnostics shares witnessed an impressive listing on the stock exchanges on August 17, 2026. The stock listed at a premium of 21.44% over the IPO price of ₹807 per share.

Molbio Diagnostics share price opened at ₹980 per scrip on NSE and BSE, registering a gain of ₹173 per share over the IPO issue price. At the time of listing, the company’s market valuation stood at ₹11,293.52 crore.

The listing price of Molbio Diagnostics was better than the grey market price (GMP) indicated before the stock began trading on exchanges.

Molbio Diagnostics Share Price Movement After Listing

As of the time of writing this article, Molbio Diagnostics shares were trading at ₹[latest price]. The stock listed at ₹980 per share on NSE and BSE. Hence, Molbio Diagnostics shares have moved [₹change / %change] from the listing price.

It is pertinent to note that the share price of Molbio Diagnostics may change frequently throughout the trading day. Therefore, investors must check the latest market price of Molbio Diagnostics shares before buying/selling on the stock exchanges.

Molbio Diagnostics GMP Before Listing

Before listing, Molbio Diagnostics shares were in demand in the grey market, registering a GMP of ₹116 or 14.37% over the IPO price of ₹807 per share, as per the data by Investorgain on morning of August 17, 2026.

As per the GMP, the expected listing price of Molbio Diagnostics shares was around ₹923, implying a gain of 14.37%. However, Molbio Diagnostics listed at ₹980, registering a 21.44% gain, beating the grey market price.

It is important to mention that GMP for any stock is an unofficial and non-regulated indicator, which implies that it may not be accurate or reliable. Hence, investors must not rely on GMP while making investment decisions.

Molbio Diagnostics IPO Details

The ₹939.70 crore Molbio Diagnostics IPO opened for subscription on August 10, 2026, and remained open until August 12, 2026. The issuing company had decided to keep the price band of ₹768-₹807 per equity share. The final issue price of Molbio Diagnostics IPO came out at ₹807 per share.

The ₹939.70 crore IPO issue consisted of a fresh issuance worth ₹200 crore and an offer for sale (OFS) of ₹739.70 crore.

The IPO received a massive demand from investors, being subscribed 70.27 times in total. In terms of demand, the Qualified Institutional Buyers (QIB) category was subscribed 186.39 times, the Non-Institutional Investor (NII) category was subscribed 49.80 times and the retail category was subscribed 12.96 times.

The total number of bids received for Molbio Diagnostics IPO amounted to 57,32,14,392 equity shares against the aggregate offer of 81,58,529 equity shares.

Molbio Diagnostics IPO Key Details

Particulars Details IPO Size ₹939.70 crore IPO Price Band ₹768–₹807 per share Issue Price ₹807 per share Listing Price (NSE): ₹980 Listing Price (BSE): ₹980 Listing Gain 21.44% Overall Subscription 70.27 times IPO Opening Date August 10, 2026 IPO Closing Date August 12, 2026 Pre-listing GMP ₹116.

About Molbio Diagnostics

Molbio Diagnostics is a Goa-based healthcare technology company, which develops and commercialises point-of-care diagnostic solutions. The company’s innovative Truenat platform provides portable, rapid and reliable molecular diagnostic testing with real-time PCR at primary care levels.

Truenat is a decentralized POC molecular diagnostics platform, which enables testing for a range of diseases from the comfort of one’s home or local clinics. Molbio Diagnostics has developed assays for more than 30 diseases and has five manufacturing units located across the country.

Molbio Diagnostics offers its diagnostic products and kits for the healthcare and hospital sector, government programs, diagnostic laboratories and other related industries. The company has planned to utilise the fresh issue proceeds for capital expenditure for setting up infrastructure for the R&D centre, Centre of Excellence and connected office spaces. Funds will also be used to buy plant, machinery and other allied equipment needed for its manufacturing units at Goa and Visakhapatnam.

Molbio Diagnostics Listing: Key Takeaways

Molbio Diagnostics registered a strong listing on August 17, with its shares listing at ₹980 on NSE and BSE, which is 21.44% higher than the IPO issue price of ₹807 per share. Since then, Molbio Diagnostics shares have been witnessing a demand from investors, fuelled by a higher subscription during IPO (70.27 times) and a strong GMP before listing at ₹116.

However, investors must keep in mind that the future price trajectory of Molbio Diagnostics shares depends on various factors, which include the company’s performance and market sentiments surrounding it. Therefore, it is advised that investors monitor the latest Molbio Diagnostics share price movement on the stock exchanges and conduct extensive research before considering buying the scrip.

Stay updated with all the latest IPO news with PL Capital.

Disclaimer: Investments in securities market are subject to market risks, read all the related documents carefully before investing.

This is a knowledge-sharing initiative by PL Capital. The information provided is only for educational purposes and should not be considered as financial advice & has no influence on the investment/trading decisions of any investors.

For detailed disclaimers/disclosure and Mandatory terms and conditions please visit our website https://www.plindia.com/regulatory-content/